DZ Bank’s Cymabay Therapeutics CBAY Stock Holding History

DZ Bank’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-17,000	Closed	-$221K	–	1120
2018 Q1	$221K	Buy	+17,000	New	+$211K	﹤0.01%	917

Other funds holding CBAY

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

DZ Bank's CBAY Position: Q2 2018 in Review

DZ Bank sold out of Cymabay Therapeutics (CBAY) in Q2 2018, closing a stake of 17,000 shares — an estimated $221K sold.

DZ Bank first reported a position in CBAY in Q1 2018 and held it in 1 quarter. The position peaked at $221K in Q1 2018. 118 funds tracked by Wall St. Rank hold CBAY as of Q2 2018.

DZ Bank reported no remaining Cymabay Therapeutics position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 17,000 Cymabay Therapeutics shares in Q2 2018, an estimated $221K.
DZ Bank first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 1 quarter.
DZ Bank's Cymabay Therapeutics position peaked at $221K in Q1 2018.
118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.